Is Amgen Inc (AMGN) a good stock to buy?
In the past three months, Amgen insiders have not sold or bought any company stock. Only 0.36% of the stock of Amgen is held by insiders. 74.95% of the stock of Amgen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
What are analysts'1 year price targets for Amgen's stock?
20 analysts have issued 1 year price objectives for Amgen's stock. Their predictions range from $189.00 to $243.00. On average, they expect Amgen's stock price to reach $217.29 in the next twelve months. This suggests a possible upside of 6.9% from the stock's current price.
What was Amgen’s price move in the latest trading session?
Amgen (AMGN) closed at $229.21 in the latest trading session, marking a +0.16% move from the prior day. © 2022 Yahoo. All rights reserved.
Is Amgen's (AMGN) PE ratio too expensive?
Earnings for Amgen are expected to grow by 6.95% in the coming year, from $16.83 to $18.00 per share. The P/E ratio of Amgen is 22.02, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 15.35.
See more
Is Amgen a buy sell or hold?
Amgen has received a consensus rating of Hold. The company's average rating score is 2.14, and is based on 3 buy ratings, 10 hold ratings, and 1 sell rating.
Is Amgen a good buy?
Amgen Inc. may be undervalued. Its Value Score of B indicates it would be a good pick for value investors. The financial health and growth prospects of AMGN, demonstrate its potential to outperform the market. It currently has a Growth Score of A.
How much is Amgen?
$ 245.56CloseChgChg %$245.78-0.85-0.34%
How many times has Amgen split?
According to our Amgen stock split history records, Amgen has had 5 splits.
Is AMGN a buy now?
Out of 14 analysts, 2 (14.29%) are recommending AMGN as a Strong Buy, 1 (7.14%) are recommending AMGN as a Buy, 11 (78.57%) are recommending AMGN as a Hold, 0 (0%) are recommending AMGN as a Sell, and 0 (0%) are recommending AMGN as a Strong Sell.
Does Amgen stock pay dividends?
THOUSAND OAKS, Calif. , Dec. 3, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.94 per share dividend for the first quarter of 2022. The dividend will be paid on March 8, 2022 , to all stockholders of record as of the close of business on February 15, 2022 .
Is Amgen a stable company?
Amgen is a very good company to work for if you are looking for very good benefits and salary. Benefits, pay, culture, professionalism. Some of the best time off of any company in the biotechnology industry. Unstable environment at the present.
What happened today Amgen?
Amgen (AMGN) closed the most recent trading day at $246.63, moving -0.28% from the previous trading session.
What is Amgen best known for?
Amgen is one of the world's leading biotechnology companies. Amgen is a values-based company, deeply rooted in science and innovation to transform new ideas and discoveries into medicines for patients with serious illnesses.
What companies has Amgen bought?
Strategic partners and acquisitions. Amgen also acquires Micromet Inc., developers of what would later be approved by the FDA as BLINCYTO® (blinatumomab); KAI Pharmaceuticals, developers of AMG 416; and Mustafa Nevzat, a leading privately held Turkish pharmaceutical company.
What company owns Amgen?
The Vanguard Group, Inc. SSgA Funds Management, Inc. PRIMECAP Management Co.
What company did Amgen buy?
- July 16, 2002 - Amgen Inc. (Nasdaq: AMGN), the world's largest biotechnology company, announced today that it has completed its acquisition of Immunex Corporation (Nasdaq: IMNX), a leader in inflammation and one of biotechnology's premier companies.
When will Amgen report its third quarter results?
Did Amgen beat analysts' expectations?
Amgen (NASDAQ: AMGN) reported its third-quarter results on Nov. 2, 2021. In this Motley Fool Live video recorded on Nov. 3, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss the highlights from the big biotech's Q3 update. A big biotech also announced Q3 results on Tuesday.
What is the ticker symbol for Amgen?
Amgen beat analysts' earnings expectations in the third quarter, and its balance sheet remains admirable.
How much of Amgen stock is held by institutions?
Amgen trades on the NASDAQ under the ticker symbol "AMGN."
What is the dividend payout ratio of Amgen?
74.95% of the stock of Amgen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
How much does Amgen make?
Amgen does not yet have a strong track record of dividend growth. The dividend payout ratio of Amgen is 42.41%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Amgen will have a dividend payout ratio of 39.09% next year.
Where is Amgen located?
Amgen has a market capitalization of $140.58 billion and generates $25.42 billion in revenue each year. The medical research company earns $7.26 billion in net income (profit) each year or $16.60 on an earnings per share basis.
What is Amgen's FY 2021 earnings?
Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company can be reached via phone at (805) 447-1000, via email at [email protected], or via fax at 805-447-1010.
When is Amgen earnings call?
Amgen updated its FY 2021 earnings guidance on Tuesday, November, 9th. The company provided EPS guidance of $16.500-$17.100 for the period, compared to the Thomson Reuters consensus estimate of $16.430. The company issued revenue guidance of $25.80 billion-$26.20 billion, compared to the consensus revenue estimate of $26.01 billion.
Sales
Risks
- 17 Wall Street analysts have issued 12 month price objectives for Amgen's stock. Their forecasts range from $179.00 to $232.00. On average, they anticipate Amgen's share price to reach $207.4706 in the next year. This suggests a possible upside of 20.7% from the stock's current price. View Analyst Price Targets for Amgen.
Ratings
- 17 Wall Street analysts have issued \"buy,\" \"hold,\" and \"sell\" ratings for Amgen in the last year. There are currently 9 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of \"Hold.\" View Analyst Ratings for Amgen.
Reception
- Media stories about AMGN stock have trended somewhat positive on Sunday, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most f…
Ownership
- Amgen's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.56%), Wells Fargo & Company MN (1.23%), LSV Asset Management (0.64%), Sumitomo Mitsui Trust Holdings Inc. (0.41%), Dimensional Fund Advisors LP (0.39%) and Parametric Portfolio Associates LLC (0.38%). Company insiders that own Amge…
Business
- Amgen has a market capitalization of $104.82 billion and generates $23.75 billion in revenue each year. The medical research company earns $8.39 billion in net income (profit) each year or $14.40 on an earnings per share basis. Amgen employs 21,500 workers across the globe.
Infrastructure
- Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company can be reached via phone at 805-447-1000 or via email at [email protected].